top of page

Hylomorph secures CHF 4.5m in Series B2 financing round alongside non-dilutive funds from Swiss Accelerator to help patients undergoing implant surgery

Zurich, Switzerland – September 2023

 

Hylomorph AG, a Switzerland based spin-off from ETH Zurich, has closed an oversubscribed Series B2 financing round worth CHF 4.5 million (USD 5.1 million) with leading healthcare investors. The financing round was led by EFI Lake Geneva Ventures, joined by the existing shareholders Start Angels Network Switzerland, Zürcher Kantonalbank, Verve Ventures, and Interconsult, and followed by Club degli Investitori, Excellis Holding, and other Business Angels. In addition, the company has secured CHF 2.4 million (USD 2.7) in non-dilutive funds from the Innosuisse Swiss Accelerator Grant program.

This significant funding marks a major milestone for Hylomorph as it continues pursuing its mission to make substantial impact on patients’ care. The investment will help expand Hylomorph’s products portfolio, as well as achieve regulatory approvals and market launch for their first indication in cardiology. In particular, the Swiss Accelerator funding will support the company’s clinical development program, to test safety and efficacy in a large group of patients suffering Cardiac Rhythm Management disorders.

"We are thrilled to have successfully closed this financing round, with EFI Lake Geneva Venture leading the investment, and to be awarded the competitive Swiss Accelerator grant. With this capital injection, we will provide patients with multiple solutions for the prevention of post operative-complications. Our first commitment is on patients requiring device therapy to treat arrhythmia or cardiac arrests, where we have experienced great momentum with the clinical and industrial community. We are also exploring new indications in neurostimulation as well as the integration of therapeutic agents, to increase the benefits and wellbeing of our patients" said Simone Bottan, CEO and co-founder at Hylomorph.

“This new financing round empowers us to drive innovation and elevate patient care to new heights. Our dedicated team's passion and expertise have been instrumental in reaching this milestone, and we are grateful for their tireless efforts. Together, with the invaluable support of our investors and team, we are committed to revolutionizing medical device technology and making a lasting impact on global healthcare” said Giovanni Leo, Partner at EFI Lake Geneva Venture.

About Hylomorph:

Hylomorph Medical is a medical technology company dedicated to developing innovative solutions that improve patient outcomes following implant surgery. With a focus on making a substantial impact on healthcare practices, Hylomorph’s portfolio of cutting-edge products aims to enhance the quality of life for individuals worldwide.

For further information please visit

www.hylomorph-medical.com and www.linkedin.com/company/hylomorph-ag

 

 

Media Contact: here

bottom of page